XML 24 R10.htm IDEA: XBRL DOCUMENT
v3.24.3

REVENUES | 9 Months Ended
--- | ---
Sep. 30, 2024
REVENUES |
REVENUES | NOTE 4 – REVENUES The following table summarizes the Company’s disaggregation of revenues: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Nine Months Ended September 30, | ​ |  | ​ | Three Months Ended September 30, | ​
(U.S. dollars in thousands) |  | 2024 |  | 2023 | ​ | ​ | ​ | 2024 |  | 2023 | ​
Pfizer | ​ | $ | 11,431 | ​ | $ | 7,972 | ​ | ​ | ​ | $ | 3,430 | ​ | $ | 2,304 | ​
Brazil | ​ | $ | 9,314 | ​ | $ | 5,120 | ​ | ​ | ​ | $ | 2,048 | ​ | $ | 2,320 | ​
Chiesi | ​ | $ | 14,075 | ​ | $ | 17,217 | ​ | ​ | ​ | $ | 12,361 | ​ | $ | 5,544 | ​
Total revenues from selling goods | ​ | $ | 34,820 | ​ | $ | 30,309 | ​ | ​ | ​ | $ | 17,839 | ​ | $ | 10,168 | ​
Revenues from license and R&D services | ​ | $ | 361 | ​ | $ | 24,699 | ​ | ​ | ​ | $ | 120 | ​ | $ | 177 | ​
​

X
- Definition The entire disclosure pertaining to revenue. + References No definition available. + Details
Name: | plx_RevenueDisclosureTextBlock
Namespace Prefix: | plx_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueRecognitionAndDeferredRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration